How Boehringer In­gel­heim and Pfiz­er bat­tled over the ex­clu­siv­i­ty of the first Hu­mi­ra in­ter­change­able

Ten com­pa­nies are now com­pet­ing for mar­ket share with Ab­b­Vie’s megablock­buster rheuma­toid arthri­tis drug Hu­mi­ra (adal­i­mum­ab), but two of those com­peti­tors — Pfiz­er and Boehringer In­gel­heim …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER